Cassava Sciences Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while iShares 7-10 Year Treasury Bond ETF trades at $89.42 (market cap $41.24B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 1046.7× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 9,141,967). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and iShares 7-10 Year Treasury Bond ETF for 108 Days on average.
| FLNA | IEF | |
|---|---|---|
Market Cap | $39.40M | $41.24B |
Volume | 759,018 | 9,141,967 |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $97.99 |
52-Week Low | $0.68 | $88.92 |
Typical Hold Time | 37 Days | 108 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
IEF trades at $89.11, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bearish trend with moving averages overwhelmingly negative, though oscillators suggest potential oversold conditions. Recent dividend distributions of $0.31-$0.33 per share provide income support. The bond ETF faces headwinds from rising Treasury yields and inflation concerns, with market sentiment leaning defensive amid ongoing bond market volatility.
The outlook remains cautious as IEF navigates the highest Treasury yields in decades. While current yields create potential entry points for income-focused investors, persistent inflation and Federal Reserve policy uncertainty pose significant risks. The ETF's defensive positioning may appeal during market turbulence, but further yield increases could pressure prices lower.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →